Welcome to Evidence Corner. Here we try to explain the data behind the clinical decisions we make through deep-diving studies that have shaped how we treat patients with liver disease. For each clinical question, we’ve chosen a single study and with our digestible slides, we try to concisely highlight the key aspects of the study.
https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.32244 More benefits of good glycemic control in patients with NAFLD!
https://pubmed.ncbi.nlm.nih.gov/35029163/ Turns out, ECGs aren’t just for the heart!
How does one prognosticate outcomes in pediatric primary sclerosing cholangitis? https://pubmed.ncbi.nlm.nih.gov/32464706/
Are there any treatment options for medical management of NASH? Find out in this summary of the PIVENS Trial!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224127/ Can a simple, inexpensive supplement decrease risk of liver decompensation?
Hepatic encephalopathy after TIPS is common. So how do we prevent it?
Learn how covid-19 vaccination affects outcomes in patients with liver disease
Does the stage of fibrosis predict outcomes in NAFLD?
Do you have suggestions for topics within this series? Are you a fellow interested in contributing? Please feel free to reach out via Twitter to the fellow lead or to Liver Fellow Network directly. You can also e-mail us at email@example.com.